Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

New insights into osteoclastogenic signaling mechanisms.

Nakashima T, Hayashi M, Takayanagi H.

Trends Endocrinol Metab. 2012 Nov;23(11):582-90. doi: 10.1016/j.tem.2012.05.005. Epub 2012 Jun 15. Review.

PMID:
22705116
2.

New regulation mechanisms of osteoclast differentiation.

Nakashima T, Takayanagi H.

Ann N Y Acad Sci. 2011 Dec;1240:E13-8. doi: 10.1111/j.1749-6632.2011.06373.x. Review.

PMID:
22360322
3.

Osteoclastogenesis and osteoimmunology.

Feng W, Xia W, Ye Q, Wu W.

Front Biosci (Landmark Ed). 2014 Jan 1;19:758-67. Review.

PMID:
24389219
4.

[The OPG/RANKL/RANK system and bone resorptive disease].

Liu JZ, Ji ZL, Chen SM.

Sheng Wu Gong Cheng Xue Bao. 2003 Nov;19(6):655-60. Review. Chinese.

PMID:
15971575
5.

RANKL signaling in bone physiology and cancer.

Dougall WC.

Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be. Review.

PMID:
18685382
6.

Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.

Tanaka S.

Am J Nephrol. 2007;27(5):466-78. Epub 2007 Jul 25. Review. Erratum in: Am J Nephrol. 2007;27(5):544.

PMID:
17652963
7.

RANKL-RANK signaling in osteoclastogenesis and bone disease.

Wada T, Nakashima T, Hiroshi N, Penninger JM.

Trends Mol Med. 2006 Jan;12(1):17-25. Epub 2005 Dec 13. Review.

PMID:
16356770
8.

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).

Liu W, Zhang X.

Mol Med Rep. 2015 May;11(5):3212-8. doi: 10.3892/mmr.2015.3152. Epub 2015 Jan 7. Review.

PMID:
25572286
9.

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.

Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.

Bone. 2007 Apr;40(4):981-90. Epub 2006 Dec 28.

PMID:
17196895
10.

Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.

Chen T, Feng X.

Assay Drug Dev Technol. 2006 Aug;4(4):473-82. Review.

PMID:
16945019
11.

Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.

Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G.

Cancer Treat Rev. 2015 Feb;41(2):61-8. doi: 10.1016/j.ctrv.2014.12.001. Epub 2014 Dec 8. Review.

PMID:
25499997
12.

The RANK/RANKL/OPG triad in cancer-induced bone diseases.

Dougall WC, Chaisson M.

Cancer Metastasis Rev. 2006 Dec;25(4):541-9. Review.

PMID:
17180711
13.

The dynamic interplay between osteoclasts and the immune system.

Nakashima T, Takayanagi H.

Arch Biochem Biophys. 2008 May 15;473(2):166-71. doi: 10.1016/j.abb.2008.04.004. Epub 2008 Apr 8. Review.

PMID:
18410741
14.

RANK/RANKL: regulators of immune responses and bone physiology.

Leibbrandt A, Penninger JM.

Ann N Y Acad Sci. 2008 Nov;1143:123-50. doi: 10.1196/annals.1443.016. Review.

PMID:
19076348
15.

Osteoclasts and the immune system.

Nakashima T, Takayanagi H.

J Bone Miner Metab. 2009;27(5):519-29. doi: 10.1007/s00774-009-0089-z. Epub 2009 May 20. Review.

PMID:
19455385
16.

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T.

Nature. 2000 Nov 30;408(6812):600-5.

PMID:
11117749
17.

Mechanistic insight into osteoclast differentiation in osteoimmunology.

Takayanagi H.

J Mol Med (Berl). 2005 Mar;83(3):170-9. Epub 2005 Jan 26. Review.

PMID:
15776286
18.

Inflammatory bone destruction and osteoimmunology.

Takayanagi H.

J Periodontal Res. 2005 Aug;40(4):287-93. Review.

PMID:
15966905
19.

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.

Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D.

Cell Mol Life Sci. 2007 Sep;64(18):2334-50. Review.

PMID:
17530461
20.

Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies.

Anandarajah AP, Schwarz EM.

Adv Exp Med Biol. 2009;649:85-99. Review.

PMID:
19731622

Supplemental Content

Support Center